The Company’s E-Commerce and Retail
Business Segments are Both Experiencing Strong Levels of
Growth
NEW YORK, NY -- August 16, 2021 -- InvestorsHub NewsWire --
Tauriga Sciences, Inc. (OTCQB: TAUG)
(“Tauriga” or the “Company”), a New York based diversified Life
Sciences Company, has today published a positive Mid-Quarter update
for its 2ndFiscal Quarter 2022 (Period: July 1st–
September 30th, 2021). Over the past few weeks, the
Company has acquired inventory for all of its new and enhanced
products and product lines. The Company was materially
affected by COVID-19 related production delays, between the months
of May-July 2021. The Company was negatively affected by
these delays, during its 1stFiscal Quarter 2022 (Period:
April 1st– June 30th, 2021). However, these substantial
product delivery issues (relating to availability of inventory) are
no longer adversely affecting the Company – as of today’s
date. The Company has been able to operate at full capacity,
since approximately August 1, 2021.
The Company has already generated record Quarterly revenue (net
revenue), in just the first 6 weeks of this Quarter. The Company’s
E-Commerce and Retail business segments are both experiencing
strong levels of growth and demand. The Company’s recent
commercial launch of its enhanced Tauri-Gum™ product line (11 SKUs
in Total) has accelerated revenue growth over the past 2
weeks. The Company’s gross margins have continued to
improve as well.
The Company has been in discussions with a number of potential
distributors, large retail customers, joint venture partners,
international vendors, and professional athlete(s). The
Company is confident in its ability to consummate agreements that
have the potential create shareholder value.
In addition, the Company has recently increased its product
offerings on Amazon.com (“Amazon”) – to include its Cherry Lime
Rickey flavor 50mg Caffeine Infused Tauri-Gum™. The
Company’s product sales on Amazon continue to increase as
well.
Amazon Link (Cherry Lime Rickey
Tauri-Gum™):
https://www.amazon.com/Pack-Taurigum-Caffeine-Chewing-Gum/dp/B09C8YQ3TP/ref=sr_1_5?dchild=1&keywords=Tauri-Gum+caffeine&qid=1629080403&sr=8-5
Lastly, the Company is continuing to progress in its ongoing
Pharmaceutical development efforts. This relates to the
development of a proposed, Cannabinoid based, Pharmaceutical grade
version of Tauri-Gum™ - for nausea regulation (specifically
designed for the following indication: Patients Subjected to
Ongoing Chemotherapy Treatment). The Company expects to issue a
comprehensive update on such efforts within the near
term.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating,
diversified life sciences company, engaged in several major
business activities and initiatives. The company
manufactures and distributes several proprietary retail products
and product lines, mainly focused on the Cannabidiol (“CBD”) and
Cannabigerol (“CBG”) Edibles market segment. The main
product line, branded as Tauri-Gum™, consists of a proprietary
supplement chewing gum that is Kosher certified, Halal certified,
and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood
Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon,
Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen
Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini),
(Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), &
(Vitamin D3 Infused Tauri-Gum™ Flavor: Golden
Raspberry). The Company’s commercialization strategy
consists of a broad array of retail customers, distributors, and a
fast-growing E-Commerce business segment (E-Commerce
website: www.taurigum.com). Please visit our corporate
website, for additional information, as well as inquiries,
at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing
Pharmaceutical Development initiative. This relates to the
development of a proposed Pharmaceutical grade version of
Tauri-Gum™, for nausea regulation (specifically designed for the
following indication: Patients Subjected to Ongoing Chemotherapy
Treatment). On March 22, 2021, the Company announced that it had
Converted its U.S. Provisional Patent Application (filed on March
17, 2020) into a U.S. Non-Provisional Patent
Application. The Patent, filed with the U.S.P.T.O. is
Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND
METHODS OF TREATMENT”. On December 18, 2020 the Company
disclosed that it had entered into a Master Services Agreement with
CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New
York. In addition, the Company operates two full time
E-Commerce fulfillment centers: one located in Montgomery, Texas
and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements”
as defined by the Private Securities Litigation Reform Act of 1995
which represent management’s beliefs and assumptions concerning
future events. These forward-looking statements are often indicated
by using words such as “may,” “will,” “expects,” “anticipates,”
believes, “hopes,” “believes,” or plans, and may include statements
regarding corporate objectives as well as the attainment of certain
corporate goals and milestones. Forward-looking statements are
based on present circumstances and on management’s present beliefs
with respect to events that have not occurred, that may not occur,
or that may occur with different consequences or timing than those
now assumed or anticipated. Actual results may differ materially
from those expressed in forward looking statements due to known and
unknown risks and uncertainties, such as are not guarantees of
general economic and business conditions, the ability to
successfully develop and market products, consumer and business
consumption habits, the ability to consummate successful
acquisition and licensing transactions, fluctuations in exchange
rates, and other factors over which Tauriga has little or no
control. Many of these risks and uncertainties are discussed in
greater detail in the “Risk Factors” section of Tauriga’s Form 10-K
and other periodic filings made from time to time with the
Securities and Exchange Commission. Such forward-looking statements
are made only as of the date of this release, and Tauriga assumes
no obligation to update forward-looking statements to reflect
subsequent events or circumstances. You should not place undue
reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Sep 2023 to Sep 2024